Explore the words cloud of the IMaP project. It provides you a very rough idea of what is the project "IMaP" about.
The following table provides information about the project.
Coordinator |
KAROLINSKA INSTITUTET
Organization address contact info |
Coordinator Country | Sweden [SE] |
Total cost | 203˙852 € |
EC max contribution | 203˙852 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2018 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2020 |
Duration (year-month-day) | from 2020-08-01 to 2022-07-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | KAROLINSKA INSTITUTET | SE (STOCKHOLM) | coordinator | 203˙852.00 |
The p53 protein is mutated in over 50% of cancers. Because its expression often promotes tumor growth and is associated with resistance to treatment, there has been great interest in treating cancers based on p53 mutation status. However, the use of p53- targeted therapies requires knowing the mutation status. DNA sequencing is one approach, but requires invasive biopsies, and newer sequencing techniques still face technical hurdles. Non-invasive imaging techniques offer an alternative approach for detecting mutation status. Given that p53 regulates blood vessel growth, and that vessel imaging is used clinically to monitor response to cancer therapy, I hypothesize that tumor vessels could be used as an imaging marker to identify p53 mutation status. To test this hypothesis, I will measure relationships between p53 mutations and vessel structure/function using my expertise in 3D cell biology, vessel imaging, and image analysis and the unique expertise of the host lab in p53 biology, proteomics, and flow cytometry. The objectives of this interdisciplinary work are: 1) to screen the effect of p53 mutants on vessel structure in vitro; 2) to characterize the molecular response of endothelial cells to p53-targeted therapies; and 3) to image the structure and function of vessels in mutant p53 tumors in vivo. If a relationship is found between p53 mutation status and tumor vessel features, then it could lead to the development of the first imaging marker of p53 mutation status. This marker could help clinicians select p53-directed therapies to personalize therapy for each cancer patient. Apart from scientific impact, the proposed work will also expand my career prospects and scientific network in Europe. Under the mentorship of the host lab supervisor Prof. Sir David Lane, who discovered p53, I will receive focused training to strengthen and diversify the scientific and transferable skills I need to transition from postdoctoral scientist to junior group leader.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMAP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMAP" are provided by the European Opendata Portal: CORDIS opendata.